The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Open accessAbstract
Leukocytes contribute to the pathogenesis of thrombosis in essential thrombocythemia (ET) through recently discovered mechanisms of activation and interaction with platelets and endothelial cells. To evaluate whether an increased leukocyte count was associated with thrombosis and whether this effect can be modulated by therapy, we analyzed the clinical course of 439 patients with ET followed at the Ospedali Riuniti di Bergamo. The strength of the association was measured at diagnosis or before thrombotic events by multivariable analyses carried out using data at baseline as well as time-varying covariates. The results showed that (1) an increased leukocyte count at diagnosis was associated with thrombosis during follow-up (“baseline analysis,” relative risk [RR] 2.3, 95% confidence interval [CI] 1.4-3.9, P = .001); (2) hydroxyurea (HU) lowered leukocytosis and reduced the strength of the association between leukocytosis and thrombosis (“time-dependent analysis,” RR 1.6, 95% CI 0.9-2.0, not significant [NS]); (3) the association of leukocytosis and thrombosis was more evident in untreated low-risk patients (RR 2.7, 95% CI 1.2-6.4, P = .01) compared with HU-treated high-risk patients (RR 1.6, 95% CI 0.8-3.2, NS); and (4) the presence of JAK2 V617F was not identified as a risk factor for thrombosis during follow-up despite a significant association between the mutation and leukocytosis. We suggest validation of these findings in prospective clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Self-citationStuart, M. J., & Nagel, R. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17192-4 · Cited by 819
Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
Elliott, M. A., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05277.x · Cited by 473
Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F., & Barbui, T. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.556 · Cited by 465
Self-citationMurphy, S., Peterson, P., Iland, H., & Laszlo, J. (1997) · PubMed · Cited by 404
Wolanskyj, A. P., Schwager, S. M., McClure, R. F., Larson, D. R., & Tefferi, A. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.2.159 · Cited by 329
Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events
Grau, A. J., Boddy, A. W., Dukovic, D. A., Buggle, F., Lichy, C., Brandt, T., & Hacke, W. (2004) · Stroke · doi:10.1161/01.str.0000124122.71702.64 · Cited by 308
Cited by
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease
Jaiswal, S., & Libby, P. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0247-5 · Cited by 386
Passamonti, F., Thiele, J., Girodon, F., Rumi, E., Carobbio, A., Gisslinger, H., Kvasnicka, H. M., Ruggeri, M., Randi, M. L., Gangat, N., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403279 · Cited by 277
Self-citationJAK2V617F-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure
Sano, S., Wang, Y., Yura, Y., Sano, M., Oshima, K., Yang, Y., Katanasaka, Y., Min, K.-D., Matsuura, S., Ravid, K., et al. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.013 · Cited by 170
Metadata
- Authors
- Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A., & Barbui, T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-11-16
- Volume
- 109
- Issue
- 6
- Pages
- 2310-2313
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2064690570
- Cited by
- 320
- References
- 20
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. https://app.cochat.ai/papers/10.1182/blood-2006-09-046342
- The paper
- Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A., & Barbui, T. (2007). Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. https://doi.org/10.1182/blood-2006-09-046342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.